[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Cabrera et al., 2012 - Google Patents

Targeting regulatory T cells in the treatment of type 1 diabetes mellitus

Cabrera et al., 2012

View HTML
Document ID
18137286030426696378
Author
Cabrera S
Rigby M
Mirmira R
Publication year
Publication venue
Current molecular medicine

External Links

Snippet

Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells (Teffs) …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Cabrera et al. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus
Staeva-Vieira et al. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes
Croft et al. The significance of OX40 and OX40L to T‐cell biology and immune disease
Randolph et al. Cd4+ Cd25+ regulatory T cells and their therapeutic potential
Shirwan CHRONIC ALLOGRAFT REJECTION: Do the Th2 Cells Preferentially Induced by Indirect Alloantigen Recognition Play a Dominant Role?: 1
Petrillo et al. GITR+ regulatory T cells in the treatment of autoimmune diseases
US9018006B2 (en) Stable Tregs and related materials and methods
Barcala Tabarrozzi et al. Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus
Bone et al. Combination immunotherapy for type 1 diabetes
US10751370B2 (en) Immunomodulatory compositions
Golshayan et al. From current immunosuppressive strategies to clinical tolerance of allografts
AU2016296741A1 (en) PD-L1 expressing hematopoietic stem cells and uses
Chen et al. Mechanistic basis of immunotherapies for type 1 diabetes mellitus
Zhang et al. Adoptive cell therapy using antigen-specific CD4− CD8− T regulatory cells to prevent autoimmune diabetes and promote islet allograft survival in NOD mice
Itoh et al. Soluble CD137 ameliorates acute type 1 diabetes by inducing T cell anergy
JP2000509604A (en) Use of interleukin-10 to generate suppressor cell populations
Vlad et al. CD8+ T suppressor cells and the ILT3 master switch
Sheehy et al. Targeting type 1 diabetes: selective approaches for new therapies
Chen et al. Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby
Azimzadeh et al. Immunobiology of transplantation: impact on targets for large and small molecules
Scherm et al. Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other
ElEssawy et al. Type 1 diabetes and T regulatory cells
Chatenoud et al. Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse
Chhabra et al. Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation
Kleijwegt et al. Infectious tolerance as candidate therapy for type 1 diabetes: transfer of immunoregulatory properties from human regulatory T cells to other T cells and proinflammatory dendritic cells